24.06.2021 Cannovum AG  DE000A2LQU21

DGAP-News: Cannovum AG enters supply agreement for medical cannabis with Aurora Europe


 

DGAP-News: Cannovum AG / Key word(s): Product Launch
Cannovum AG enters supply agreement for medical cannabis with Aurora Europe

24.06.2021 / 09:06
The issuer is solely responsible for the content of this announcement.


Cannovum AG (stock exchanges Düsseldorf, Munich, Hamburg, Berlin, gettex: ISIN DE000A2LQU21) has entered into a long term supply agreement with Aurora through its licensed subsidiary, Cannovum Health eG. Starting today, Cannovum will distribute the full range of medical cannabis products offered by Aurora to pharmacies throughout Germany.

The canadian company Aurora is one of the largest authorised manufacturers of medical cannabis in the European Union. After the German legalization of medical cannabis in 2017 Aurora joined the German market with their acquisition of the German company Pedanios, thus making Aurora / Pedanios products one of the first cannabis medicines available in Germany. This allowed doctors and pharmacists to gain experience in treating their patients with these products.
Expanding the medical cannabis portfolio with the full range of Aurora products is therefore an important step for Cannovum towards ensuring best possible patient care.

"We want to support doctors and pharmacists in finding the appropriate treatment for their patients. In order for us to achieve that, we need to provide a full portfolio of medical cannabis which gives them the opportunity to fully customize the therapy. By partnering with Aurora we are confident that we continue to provide high quality medication to ensure every patient receives the best therapy", says Pia Marten, CEO of Cannovum AG.

Cannovum's own team of pharmaceutical representatives has received intensive training in the new products, in order to confidently advise pharmacists and doctors.


Contact:

Linda Rasch, IR & PR, Cannovum AG
Phone +49 30 3982 163 62, [email protected]

Cannovum AG is the first German listed medical cannabis company. Through its subsidiary Cannovum Health eG, Cannovum is a fully licensed pharmaceutical wholesaler, importer and manufacturer of high-quality medical cannabis products based in Berlin. The company focuses on the import of high-quality cannabinoid products, medical-scientific education and all-encompassing distribution for simplified and facilitated access to cannabis-based therapies.

For more information, visit www.cannovum.com



24.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Cannovum AG
Rheinsberger Str. 76/77
10115 Berlin
Germany
Phone: +49 (0)30 3982 16360
E-mail: [email protected]
Internet: www.cannovum.com
ISIN: DE000A2LQU21
WKN: A2LQU2
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich
EQS News ID: 1211413

 
End of News DGAP News Service

1211413  24.06.2021 

fncls.ssp?fn=show_t_gif&application_id=1211413&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2015 2016 2017 2018 2019 2020 2021e
Umsatzerlöse1 0,00 0,00 0,00 0,00 0,09 0,00 0,00
EBITDA1,2 0,00 0,00 0,00 0,00 -0,05 -0,03 0,00
EBITDA-Marge3 0,00 0,00 0,00 0,00 -55,56 0,00 0,00
EBIT1,4 0,00 0,00 0,00 0,00 -0,05 -0,03 0,00
EBIT-Marge5 0,00 0,00 0,00 0,00 -55,56 0,00 0,00
Jahresüberschuss1 0,00 0,00 0,00 0,00 -0,05 -0,03 0,00
Netto-Marge6 0,00 0,00 0,00 0,00 -55,56 0,00 0,00
Cashflow1,7 0,00 0,00 0,00 0,00 -0,05 -0,03 0,00
Ergebnis je Aktie8 0,00 0,00 0,00 0,00 0,00 0,00 -0,05
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2020 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: M&B Treuhand

INVESTOR-INFORMATIONEN
©boersengefluester.de
Cannovum
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A2LQU2 9,000 20,85
KGV 2022e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 0,00 0,00 -915,00
KBV KCV KUV EV/EBITDA
1,81 - 0,00 -694,86
Dividende '20 in € Dividende '21e in € Div.-Rendite '21e
in %
Hauptversammlung
0,00 0,00 0,00 07.09.2021
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
62,45% 0,00% 0,00% 0,00%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Cannovum AG  ISIN: DE000A2LQU21 können Sie bei DGAP abrufen

Handel , A2LQU2 , 27N